This summary outlines the burden of targeted diseases and program implementation outcomes in Mauritania. AFRICAN REGION LDC LIC

Similar documents
This summary outlines the burden of targeted diseases and program implementation outcomes in the Niger. AFRICAN REGION LDC LIC

This summary outlines the burden of targeted diseases and program implementation outcomes in Nigeria. AFRICAN REGION

This summary outlines the burden of targeted diseases and program implementation outcomes in Guinea-Bissau. AFRICAN REGION LIC

This summary outlines the burden of targeted diseases and program implementation outcomes in Ethiopia. AFRICAN REGION LIC

This summary outlines the burden of targeted diseases and program implementation outcomes in Côte d Ivoire. AFRICAN REGION LIC

This summary outlines the burden of targeted diseases and program implementation outcomes in Mali. AFRICAN REGION LDC LIC

This summary outlines the burden of targeted diseases and program implementation outcomes in Gabon. AFRICAN REGION

This summary outlines the burden of targeted diseases and program implementation outcomes in Malawi. AFRICAN REGION LDC LIC

This summary outlines the burden of targeted diseases and program implementation outcomes in Angola. AFRICAN REGION LDC LMI

This summary outlines the burden of targeted diseases and program implementation outcomes in Rwanda. AFRICAN REGION LDC LIC

NTDs: update on the progress. Department of Control of Neglected Tropical Diseases

Module 3. Setting up an Integrated NTDP

more than 6 million people at risk of contracting one or more diseases

25 million Ghanaians are at risk of contracting one or more diseases

ETHIOPIA SCHISTOSOMIASIS AND SOIL-TRANSMITTED HELMINTHES CONTROL PROGRAMME: PROGRESS AND PROSPECTS ABSTRACT INTRODUCTION

Neglected Tropical Diseases

Partners. hygiene. progress. END in Africa & Burkina Faso. community. support health. e e e e e e e e e e e e e e e. endinafrica.

Multidrug-/ rifampicinresistant. (MDR/RR-TB): Update 2017

The Schistosomiasis Control Initiative (SCI) Professor Alan Fenwick

2004 Update. Luxembourg

Schistosomiasis and Neglected Tropical Diseases Control

NTDs Slated for Elimination and Eradication

In 1993 and 1996, 1 percent of IV drug users tested were positive. In 2000, 193 injecting drug users were screened and none tested positive.

2004 Update. Bahrain

Adult rate (%) 0.1 Low estimate. 0.0 High estimate 0.2

2004 Update. Syrian Arab Republic

2004 Update. Georgia

District NTD Training module 9 Learners Guide

2004 Update. Seychelles

MAPS ON GLOBAL TOBACCO CONTROL POLICY DATA

HIV/AIDS estimates. UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance. UNAIDS/WHO Epidemiological Fact Sheet Update.

NEGLECTED TROPICAL DISEASES AND ANEMIA - WHAT DO WE KNOW

Adult rate (%) 0.1 Low estimate. 0.0 High estimate 0.2

2004 Update. Hungary

2004 Update. Mauritius

2004 Update. Lebanon

Integrating NTD drug packages into a Child Nutrition Campaign

2004 Update. Serbia and Montenegro

WHO/NMH/TFI/11.3. Warning about the dangers of tobacco. Executive summary. fresh and alive

CUTANEOUS LEISHMANIASIS

The WHO Global Project on anti-tb drug resistance surveillance: background, objectives, achievements, challenges, next steps

HPV Vaccination Global policy perspectives Vacuna VPH Perspectivas de la política de vacunación mundial

2004 Update. Maldives

MASS TREATMENT COVERAGE FOR NTDS Somalia and neglected tropical diseases

INTEGRATING NEGLECTED TROPICAL DISEASES INTO GLOBAL HEALTH AND DEVELOPMENT

Summary of the Twelfth Meeting of the ITFDE (II) May 6, 2008

BEST PRACTICES IN MICROPLANNING FOR CHILDREN OUT OF THE HOUSEHOLD: AN EXAMPLE FROM NORTHERN NIGERIA

Immunization Update & focus on meningococcal vaccine PART 1

HIV/AIDS estimates. UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance. UNAIDS/WHO Epidemiological Fact Sheet Update.

WHO Rotavirus Vaccine Update Dr. Fatima Serhan WHO/FWC/IVB/EPI

HPV vaccine the global perspective

Regional Approaches to NTD Control in the Americas

2004 Update. Suriname

MASS TREATMENT COVERAGE FOR NTDS Togo and neglected tropical diseases

HIV/AIDS estimates. UNAIDS/WHO Working Group on Global HIV/AIDS and STI Surveillance. UNAIDS/WHO Epidemiological Fact Sheet Update.

Module 5. NTD Drug Management

2004 Update. Eritrea

RECOMMENDATIONS BASED ON THE SEVENTH MEETING OF NEGLECTED TROPICAL DISEASE REGIONAL PROGRAMME REVIEW GROUP FOR PREVENTIVE CHEMOTHERAPY (NTD-PC-RPRG)

MASS TREATMENT COVERAGE FOR NTDS Democratic Republic of the Congo and neglected tropical diseases

IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. VOLUME 93 Carbon Black, Titanium Dioxide, and Talc

Western Pacific Region Neglected Tropical Diseases News

MONITORING HEALTH INEQUALITY

2004 Update. Barbados

The Neglected Tropical Diseases of Guinea, Liberia, Sierra Leone

MONITORING THE BUILDING BLOCKS OF HEALTH SYSTEMS: A HANDBOOK OF INDICATORS AND THEIR MEASUREMENT STRATEGIES

GOOD PHARMACOPOEIAL PRACTICES

2004 Update. Croatia

WHO Library Cataloguing-in-Publication Data. World health statistics 2011.

2. Treatment coverage: 3. Quality of care: 1. Access to diagnostic services:

Policy and technical topics: Selected neglected tropical diseases targeted for elimination: kala-azar, leprosy, yaws, filariasis and schistosomiasis

2004 Update. Belarus

2004 Update. Armenia

State of InequalIty. Reproductive, maternal, newborn and child health. executi ve S ummary

CANCER FACT SHEETS: BREAST CANCER

HIV PREVENTION, DIAGNOSIS, TREATMENT AND CARE FOR KEY POPULATIONS

Jaderson Lima, MD On behalf of François Bompart, MD

The epidemiology of tuberculosis

Summary of the Twenty-Fifth Meeting of the International Task Force for Disease Eradication (ITFDE) November 8, 2016

Maternal and Neonatal Tetanus Elimination by Yes, We Can! Global Immunization Meeting 18 th February 2009

Update on Polio Vaccine Supply

Global Rotavirus Surveillance Network

Community Directed Intervention for Onchocerciasis Control and Public Health Interventions

2010 global TB trends, goals How DOTS happens at country level - an exercise New strategies to address impediments Local challenges

Thank you for joining, the M&RI webinar will begin shortly

Effective Sampling Methodology for Program Evaluation in Developing Countries

Hepatitis B vaccination worldwide: Lessons learnt and the way forward

Part I. Health-related Millennium Development Goals

Photo Book: Identify Signs of Illness

Guidelines for revising ivermectin treatment boundaries within the context of onchocerciasis elimination

CANCER FACT SHEETS: STOMACH CANCER

Integrated approaches in NTDs: practices in Brazil

CANCER FACT SHEETS: LIVER CANCER

Global Capacity for Surveillance and Response to Emerging Infectious Diseases

CANCER FACT SHEETS: ALL CANCERS EXCLUDING NON-MELANOMA SKIN CANCER

Tuberculosis: Opportunities and Challenges for Achieving HIV Epidemic Control

Transcription:

Mauritania The control of neglected tropical diseases represents a major challenge to those providing healthcare services in the endemic countries. The purpose of this country profile is to provide public health professionals with the most recently available epidemiological information on diseases for which a strategy and tools to implement large-scale preventive chemotherapy exist. This summary outlines the burden of targeted diseases and program implementation outcomes in Mauritania. BASIC COUNTRY DATA Total population 3,365,675 Population 1 years (Pre-SAC) 385,1 Population 5 1 years (SAC) 833,666 Population female 15 9 years 838,6 Population requiring preventive chemotherapy (PC) Lymphatic filariasis (LF) - Schistosomiasis (SCH) * 2,692,5 Soil-transmitted helminthiasis (STH) - Pre-SAC - - SAC - Onchocerciasis (Oncho) - Trachoma 661,691 Development status 1 Income status 2 School enrolment data Gross enrolment rate Girls enrolment ratio (gross) * Provisional estimates, to be refined LDC LIC AFRICAN REGION The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which WHO. All rights reserved Sources: Population data - United Nations, Population Division, The World Population Prospects - the 8 revision, New York, 9; Population requiring PC for STH - STH: estimates of the number of children needing preventive chemotherapy and number treated, 9. WER, N 25, 211, 86:257 268. Population requiring PC for SCH - estimates based on L.Chitsulo et al. / Acta Tropica 77()1-51; Population requiring PC for Trachoma - GET22; School enrolment data - UNESCO Institute of Statistics, Assessment. 1 United Nations classification; 2 World Bank classification. SITUATION ANALYSIS OF PREVENTIVE CHEMOTHERAPY DISEASES PCT disease Endemicity status (endemic/nonendemic) Disease distribution (Nationwide/ partial) Mapping status (Complete/in progress/not started) Implementation status (Complete/inprogress/not started) Lymphatic filariasis Schistosomiasis Endemic Partial Soil-transmitted Endemic Partial Not required helminthiasis Onchocerciasis Trachoma Loa-loa Endemic Partial 1

Maps of infection/disease endemicity Lymphatic filariasis is not present in this country Schistosomiasis, S. haematobium 7 1 28 2 56 Prevalence of SCH.h Less than 1% >=1% and <5% 5% and above Soil-transmitted helminthiasis ' WHO 8. All rights reserved Prevalence of STH Less than 2% >=2% and <5% 5% and above Onchocerciasis is not present in this country Schistosomiasis, S. mansoni 7 1 28 2 56 Prevalence of SCH.m Less than 1% >=1% and <5% 5% and above Active trachoma (TF, 1-9 years old) ' WHO 8. All rights reserved TF <5% >=5% and <1% >=1% 7 1 28 2 56 ' WHO 8. All rights reserved 7 1 28 2 56 ' WHO. All rights reserved 2

Maps of preventive chemotherapy strategy required PC strategy required - ROUND 1 1 28 2 56 7 ROUND 1 No impl./ T2 once T2 ' WHO 8. All rights reserved MDA1 (IVM+ALB), MDA2 (DEC+ALB), MDA3 (IVM), T1 (ALB or MBD + PZQ), T2 (PZQ), T3 (ALB or MBD) 3

Preventive chemotherapy implementation PREVENTIVE CHEMOTHERAPY IMPLEMENTATION 6 7 8 9 MDA1 (IVM + ALB) ROUND 1 MDA2 (DEC + ALB) MDA3 (IVM) T1 (ALB or MBD + PZQ) T2 (PZQ) T3 (ALB or MBD) A (AZI) T1 (ALB or MBD + PZQ) 698,275 523,78 75.% SAC 15,55 PreSAC 381,673 68,26 76,867 73.5% PreSAC 398,76 99,336 7,783 71.3% 35,589 2,5 57.6% 35,589 23,2 65.3% T2 (PZQ) ROUND 2 T3 (ALB or MBD) - proportion (%) of endemic districts covered with preventive chemotherapy; - proportion (%) of individuals who were treated as per the programme target.

National disease-specific coverage SCHISTOSOMIASIS * SOIL-TRANSMITTED HELMINTHIASIS Pre-SAC 5 3 1 3 5 6 7 8 12% 1% 8% 6% % 2% % * SAC SAC 7 6 5 3 1 1, 8 6 3 5 6 7 8 TRACHOMA 8 6 3 5 6 7 1% 8% 6% % 2% % 1% 8% 6% % 2% % 1% 8% 6% % 2% 5 6 7 8 9 % National disease-specific coverage - proportion (%) of individuals in the population requiring preventive chemotherapy for the specific disease (see Basic country data on page 1) that have been treated. 5

Monitoring decline of disease endemicity (in sentinel sites or periodic surveys) Data source: SCHISTOSOMIASIS Years -> S. haematobium prevalence (range) S. mansoni prevalence (range) Data source: TRACHOMA TF/TI ratio in 1-9 years old Trachomatous trichiasis males & females > 3 years old Districts achieving Ultimate Intervention Goals, % CHANCE at least 8% Years -> For more detailed information, please contact: Preventive Chemotherapy and Transmission Control, Department of Control of Neglected Tropical Diseases World Health Organization, 2, avenue Appia, 1211 Geneva 27, Switzerland We would also like to be informed as soon as possible if we have made any errors in detailing your activities or if you have any other comments. Thank you for your collaboration. Our contact e-mail is pctdata@who.int 6 World Health Organization. All rights reserved. This document is not a formal publication of WHO and does not necessarily represent the decisions or the stated policy of the Organization. The presentation of maps contained herein does not imply the expression of any opinion whatwoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delineation of its frontiers or boundaries.